Dario A. Paggiarino
Net Worth

Last updated:

What is Dario A. Paggiarino net worth?

The estimated net worth of Dr. Dario A. Paggiarino is at least $8,139,730 as of 30 Mar 2024. He owns shares worth $403,015 as insider, has earned $2,877,385 from insider trading and has received compensation worth at least $4,859,330 in EyePoint Pharmaceuticals, Inc..

What is the salary of Dario A. Paggiarino?

Dr. Dario A. Paggiarino salary is $694,190 per year as Senior Vice President & Chief Medical Officer in EyePoint Pharmaceuticals, Inc..

How old is Dario A. Paggiarino?

Dr. Dario A. Paggiarino is 68 years old, born in 1957.

What stocks does Dario A. Paggiarino currently own?

As insider, Dr. Dario A. Paggiarino owns shares in one company:

Company Title Shares Price per share Total value
EyePoint Pharmaceuticals, Inc. (EYPT) Senior Vice President & Chief Medical Officer 36,505 $11.04 $403,015

What does EyePoint Pharmaceuticals, Inc. do?

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EYPT logo
EYPT
EyePoint Pharmaceuticals, Inc.
$11.04

Dario A. Paggiarino insider trading

EyePoint Pharmaceuticals, Inc.

Dr. Dario A. Paggiarino has made 12 insider trades between 2018-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 41,050 units of EYPT stock on 30 Jun 2020. As of 30 Mar 2024 he still owns at least 36,505 units of EYPT stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 5,834 N/A N/A
Option
Common Stock 30,570 N/A N/A
Option
Common Stock 14,000 N/A N/A
Option
Restricted Stock Units 14,000 N/A N/A
Option
Restricted Stock Units 5,833 N/A N/A
Option
Common Stock 5,833 N/A N/A
Option
Common Stock 4,967 N/A N/A
Option
Restricted Stock Units 4,967 N/A N/A
Option
Stock Option (Right to Buy) 51 $13.13 $670
Sale
Common Stock 15,609 $25.41 $396,578
Sale
Common Stock 51 $25.41 $1,296
Option
Common Stock 33,665 $13.13 $442,021
Option
Stock Option (Right to Buy) 15,609 $12.9 $201,356
Option
Common Stock 51 $13.13 $670
Option
Common Stock 15,609 $12.9 $201,356
Option
Stock Option (Right to Buy) 33,665 $13.13 $442,021
Sale
Common Stock 33,665 $25.77 $867,682
Option
Common Stock 300 $12.9 $3,870
Sale
Common Stock 300 $25 $7,500
Sale
Common Stock 300 $25 $7,500
Option
Stock Option (Right to Buy) 300 $12.9 $3,870
Option
Stock Option (Right to Buy) 300 $13.13 $3,939
Option
Common Stock 300 $13.13 $3,939
Option
Stock Option (Right to Buy) 5,651 $12.9 $72,898
Option
Common Stock 5,651 $12.9 $72,898
Option
Common Stock 5,600 $13.13 $73,528
Option
Stock Option (Right to Buy) 5,600 $13.13 $73,528
Sale
Common Stock 5,651 $25.02 $141,365
Sale
Common Stock 5,600 $25.01 $140,050
Sale
Common Stock 2,039 $25 $50,975
Option
Stock Option (Right to Buy) 3,096 $13.13 $40,650
Option
Common Stock 3,096 $13.13 $40,650
Option
Stock Option (Right to Buy) 2,039 $12.9 $26,303
Option
Common Stock 2,039 $12.9 $26,303
Sale
Common Stock 3,096 $25 $77,400
Sale
Common Stock 22,913 $21.13 $484,129
Option
Stock Option (Right to Buy) 22,913 $3.26 $74,696
Option
Common Stock 22,913 $3.26 $74,696
Option
Restricted Stock Units 15,285 N/A N/A
Option
Common Stock 15,285 N/A N/A
Option
Common Stock 1,458 $10.13 $14,770
Option
Stock Option (Right to Buy) 1,458 $10.13 $14,770
Sale
Common Stock 1,458 $20 $29,160
Sale
Common Stock 30,625 $22 $673,750
Option
Common Stock 30,625 $10.13 $310,231
Option
Stock Option (Right to Buy) 30,625 $10.13 $310,231
Option
Common Stock 4,967 N/A N/A
Option
Restricted Stock Units 5,833 N/A N/A
Option
Restricted Stock Units 4,967 N/A N/A
Option
Common Stock 5,833 N/A N/A
Option
Restricted Stock Units 4,105 N/A N/A
Option
Common Stock 4,105 N/A N/A
Option
Common Stock 4,966 N/A N/A
Option
Restricted Stock Units 4,966 N/A N/A
Option
Common Stock 1,420 N/A N/A
Option
Restricted Stock Units 1,420 N/A N/A
Option
Restricted Stock Units 4,105 N/A N/A
Option
Common Stock 4,105 N/A N/A
Option
Common Stock 41,050 N/A N/A
Option
Restricted Stock Units 41,050 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Restricted Stock Units 10,000 N/A N/A
Option
Common Stock 14,200 N/A N/A
Option
Restricted Stock Units 14,200 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Restricted Stock Units 10,000 N/A N/A
Option
Common Stock 14,200 N/A N/A
Option
Restricted Stock Units 14,200 N/A N/A
Option
Restricted Stock Units 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A

EyePoint Pharmaceuticals key executives

EyePoint Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: